Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle

Toxicological Sciences

Volumn 92, Issue 2, 2006, Pages 578-586

  De Souza, Angus T ^a,b   Cornwell, Paul D ^a   Dai, Xudong ^a   Caguyong, Michelle J ^a   Ulrich, Roger G ^a  

^a ROSETTA INPHARMATICS   (United States)

^b NONE   (United States)

Author keywords

Fenofibrate; Liver; Microarray; Peroxisome proliferator ctivated receptor alpha (PPAR ); Wy 14,643

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ACETYL COENZYME A HYDROLASE; ACYL COENZYME A OXIDASE; BEZAFIBRATE; CARNITINE ACETYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CHEMOKINE; COLONY STIMULATING FACTOR; CYTOCHROME C OXIDASE; FATTY ACID; FENOFIBRATE; GLUTATHIONE TRANSFERASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INITIATION FACTOR 3; INTERMEDIATE FILAMENT PROTEIN; MANNOSIDASE; ORGANIC ANION TRANSPORTER; PANTOTHENATE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOIC ACID; ROSIGLITAZONE; SUCCINYL COENZYME A SYNTHETASE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FEMALE; GENETIC TRANSCRIPTION; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; QUADRICEPS FEMORIS MUSCLE; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE; TISSUE SPECIFICITY;

ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; FATTY ACIDS; FEMALE; GENE EXPRESSION PROFILING; GLUCOSE; LIVER; MUSCLE FIBERS, SLOW-TWITCH; MUSCLE, SKELETAL; PPAR ALPHA; PROCETOFEN; PYRIMIDINES; RATS; RATS, INBRED STRAINS; THIAZOLIDINEDIONES; TRETINOIN;

RODENTIA;

EID: 33745782050     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl019     Document Type: Article

References (52)

1. Abumrad, N. A., eL-Maghrabi, M. R., Amri, E. Z., Lopez, E., and Grimaldi, P. A. (1993). Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J. Biol. Chem. 268, 17665-17668.
2. Anai, M., Funaki, M., Ogihara, T., Kanda, A., Onishi, Y., Sakoda, H., Inukai, K., Nawano, M., Fukushima, Y., Yazaki, Y., et al. (1999). Enhanced insulin-stimulated activation of phosphatidylinositol 3-kinase in the liver of high-fat-fed rats. Diabetes 48, 158-169.
3. Ariano, M. A., Armstrong, R. B., and Edgerton, V. R. (1973). Hindlimb muscle fiber populations of five mammals. J. Histochem. Cytochem. 21, 51-55.
4. Bannwarth, B. (2002). Drug-induced myopathies. Expert Opin. Drug Saf. 1, 65-70.
5. Berger, J., and Moller, D. E. (2002). The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
6. Berger, J., and Wagner, J. A. (2002). Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol. Ther. 4, 163-174.
7. Bhanot, S., Salh, B. S., Verma, S., McNeill, J. H., and Pelech, S. L. (1999). In vivo regulation of protein-serine kinases by insulin in skeletal muscle of fructose-hypertensive rats. Am. J. Physiol. 277, E299-307.
8. Bonen, A., Dyck, D. J., Ibrahimi, A., and Abumrad, N. A. (1999). Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36. Am. J. Physiol. 276, E642-649.
9. Cornwell, P. D., De Souza, A. T., and Ulrich, R. G. (2004). Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat. Res. 549, 131-145.
10. Desvergne, B., and Wahli, W. (1999). Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev. 20, 649-688.
11. Endemann, G., Stanton, L. W., Madden, K. S., Bryant, C. M., White, R. T., and Protter, A. A. (1993). CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem 268, 11811-11816.
12. Forman, B. M., Chen, J., and Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A 94, 4312-4317.
13. Francis, G. A., Fayard, E., Picard, F., and Auwerx, J. (2003). Nuclear receptors and the control of metabolism. Anna. Rev. Physiol. 65, 261-311.
14. Furuhashi, M., Ura, N., Murakami, H., Hyakukoku, M., Yamaguchi, K., Higashiura, K., and Shimamoto, K. (2002). Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J. Endocrinol. 174, 321-329.
15. Geisbrecht, B. V., Zhang, D., Schulz, H., and Gould, S. J. (1999). Characterization of PECI, a novel monofunetional Delta(3), Delta(2)-enoyl-CoA isomerase of mammalian peroxisomes. J. Biol. Chem. 274, 21797-21803.
16. Gonzalez, F. J., Peters, J. M., and Cattley, R. C. (1998). Mechanism of action of the nongenotoxic peroxisome proliferators: Role of the peroxisome proliferator-activator receptor alpha. J. Natl. Cancer Inst. 90, 1702-1709.
17. Greenwalt, D. E., Scheck, S. H., and Rhinehart-Jones, T. (1995). Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin. Investig. 96, 1382-1388.
18. Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D. Goodyear, L. J., Kraegen, E. W., White, M. F., and Shulman, G. I. (1999). Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48, 1270-1274.
19. Halvorsen, O. (1983). Effects of hypolipidemic drugs on hepatic CoA. Biochem. Pharmacol. 32, 1126-1128.
20. Hodel, C. (2002). Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128, 159-168.
21. Hughes, T. R., Mao, M., Jones, A. R., Burchard, J., Marton, M. J., Shannon, K. W., Lefkowitz, S. M., Ziman, M., Schelter, J. M., Meyer, M. R., et al. (2001). Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat. Biotechnol. 19, 342-347.
22. Ibrahimi, A., Bonen, A., Blinn, W. D., Hajri, T., Li, X., Zhong, K., Cameron, R., and Abumrad, N. A. (1999). Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J. Biol. Chem. 274, 26761-26766.
23. Ide, T., Tsunoda, M., Mochizuki, T., and Murakami, K. (2004). Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) alpha in obese mice. Med. Sci. Monit. 10, BR388-BR395.
24. Jones, P. H., and Davidson, M. H. (2005). Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95, 120-122.
25. Keizer, H. A., Schaart, G., Tandon, N. N., Glatz, J. F., and Luiken, J. J. (2004). Subcellular immunolocalisation of fatty acid translocase (FAT)/CD36 in human type-1 and type-2 skeletal muscle fibres. Histochem. Cell Biol. 121, 101-107.
26. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc. Natl. Acad. Sci. U.S.A 94, 4318-4323.
27. Kruszynska, Y. T., Worrall, D. S., Ofrecio, J., Frias, J. P., Macaraeg, G., and Olefsky, J. M. (2002). Fatty acid-induced insulin resistance: Decreased muscle P13K activation but unchanged Akt phosphorylation. J. Clin. Endocrinol. Metab. 87, 226-234.
28. Luiken, J. J., Turcotte, L. P., and Bonen, A. (1999). Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J. Lipid. Res. 40, 1007-1016.
29. Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., et al. (1998). Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293-1301.
30. Matsui, H., Okumura, K., Kawakami, K., Hibino, M., Toki, Y., and Ito, T. (1997). Improved insulin sensitivity by bezafibrate in rats: Relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46, 348-353.
31. National Research Council (1996). The Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
32. Ramaswamy, G., Karim, M. A., Murti, K. G., and Jackowski, S. (2004). PPARalpha controls the intracellular coenzyme A concentration via regulation of PANK1alpha gene expression. J. Lipid. Res. 45, 17-31.
33. Reddy, J. K., and Hashimoto, T. (2001). Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: An adaptive metabolic system. Annu. Rev. Nutr. 21, 193-230.
34. Reibel, D. K., Wyse, B. W., Berkich, D. A., and Neely, J. R. (I 981a). Regulation of coenzyme A synthesis in heart muscle: Effects of diabetes and fasting. Am. J. Physiol. 240, H606-H611.
35. Reibel, D. K., Wyse, B. W., Berkich, D. A., Palko, W. M., and Neely, J. R. (1981b). Effects of diabetes and fasting on pantothenic acid metabolism in rats. Am. J. Physiol. 240, E597-E601.
36. Reijneveld, J. C., Knot, R. W., Bredman, J. J., Joles, J. A., and Bar, P. R. (1996). Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr. Res. 39, 1028-1035.
37. Roca, B., Calvo, B., and Monferrer, R. (2002). Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. Ann. Pharmacother. 36, 730-731.
38. Rosenson, R. S. (2004). Current overview of statin-induced myopathy. Am. J. Med. 116, 408-416.
39. Schoonjans, K., Staels, B., and Auwerx, J. (1996). Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 37, 907-925.
40. Shalev, A., Siegrist-Kaiser, C. A., Yen, P. M., Wahli, W., Burger, A. G., Chin, W. W., and Meier, C. A. (1996). The peroxisome proliferator-activated receptor alpha is a phosphoprotein: Regulation by insulin. Endocrinology 137, 4499-4502.
41. Skrede, S., and Halvorsen, O. (1979). Increased biosynthesis of CoA in the liver of rats seated with clofibrate. Eur. J. Biochem. 98, 223-229.
42. Smith, C. M., Cano, M. L., and Potyraj, J. (1978). The relationship between metabolic state and total CoA content of rat liver and heart. J. Nutr. 108, 854-862.
43. Smith, P F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H., and MacDonald, J. S. (1991). HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257, 1225-1235.
44. Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, A., Inukai, K., Asano, T., Kaburagi, Y., Ueki, K., et al. (1999). Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21, 230-235.
45. Van Nieuwenhoven, F. A., Verstijnen, C. P., Abumrad, N. A., Willemsen, P. H., Van Eys, G. J., Van der Vusse, G. J., and Glatz, J. F. (1995). Putative membrane fatty acid translocase and cytoplasmic fatty acid-binding protein are co-expressed in rat heart and skeletal muscles. Biochem. Biophys. Res. Commun. 207, 747-752.
46. Waclawik, A. J., Lindal, S., and Engel, A. G. (1993). Experimental lovastatin myopathy. J. Neuropathol. Exp. Neurol. 52, 542-549.
47. Wanders, R. J., Vreken, P., Ferdinandusse, S., Jansen, G. A., Waterham, H. R., van Roermund, C. W., and Van Grunsven, E. G. (2001). Peroxisomal fatty acid alpha- and beta-oxidation in humans: Enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem. Soc. Trans. 29, 250-267.
48. Westwood, F. R., Bigley, A., Randall, K., Marsden, A. M., and Scott, R. C. (2005). Statin-induced muscle necrosis in the rat: Distribution, development, and fibre selectivity. Toxicol. Pathol. 33, 246-257.
49. Willson, T. M., Brown, P. J., Steinbach, D. D., and Henke, B. R. (2000). The PPARs: From orphan receptors to drug discovery. J. Med. Chem 43, 527-550.
50. Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999). Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3, 397-403.
51. Ye, J. M., Doyle, P. J., Iglesias, M. A., Watson, D. G., Cooney, G. J., and Kraegen, E. W. (2001). Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 50, 411-417.
52. Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002). Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236.